In 2013, the total financing value raised by private, Biotech companies in Germany was reduced by 31% compared to last year’s figure (USD 210m from what was USD 305m in 2012). However, this summer’s snapshot of the German biotech industry, suggests that the therapeutics pipeline is revitalized, since the number of products in earlier stages of development (Pre-clinical and Phase I) increased by 112% from the year before.
Click here to download German Life Sciences Trend Analysis 2014 – 14 pages
Looking for your next Biotech or Medtech partner?
Use Biotechgate to identify new leads, licensing opportunities and management details.